Datameds AI Inc MEDS

$3.68 -0.38 (-9.36%)

Valuation

Market cap
12,982,000
Revenue TTM
$23,340,000
Net income TTM
$-101,270,000
PE ratio
0.00
Forward PE
—
Profit margin
-433.89%
Debt to equity
-1.01

Trading

Volume
1,166,700
Avg volume
7,403,886
Day's range
$3.56 – $3.94
Shares out
3,198,000
Stochastic %K
28%
Beta
-3.60
Analysts
Strong Buy
Price target
$18.74

Price

Company profile

DataMEDS AI, Inc. operates as a health IT company in the United States. The company focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units to deliver an enhanced healthcare experience for consumers. It offers tools, such as the EinsteinRx, a pharmacy dispensing AI platform; the PharmacyChain, a smart contracts platform; Patient Rx Adherence Tool; and HubR...

Show more

DataMEDS AI, Inc. operates as a health IT company in the United States. The company focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units to deliver an enhanced healthcare experience for consumers. It offers tools, such as the EinsteinRx, a pharmacy dispensing AI platform; the PharmacyChain, a smart contracts platform; Patient Rx Adherence Tool; and HubRx AI. It also operates as a pharmacy distributor; and provides clinical concierge services. DataMEDS AI, Inc., through its subsidiary develops and delivers a portfolio of products to guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. In addition, the company develops and provides functional precision medicine oncology platform. The company was formerly known as Wellgistics Health, Inc. and changed its name to DataMEDS AI, Inc. in July 2026. DataMEDS AI, Inc. was incorporated in 2022 and is based in Tampa, Florida.

Industry
Medical Distribution
Sector
Healthcare
Phone
844 203 6092
Website
https://datamedsai.com
Address
3000 Bayport Drive, Suite 950, Tampa, United States

Latest news

Stocktwits

DancingQueen69 Oct 3, 5:15 PM
$MEDS Formation of DelivMeds AI, Inc. (ticker reserved: NASDAQ:MEDS), with an expected approximate combined asset value of $4 billion, is subject to an independent fairness opinion. https://www.nasdaq.com/press-release/wellgistics-health-and-datavault-ai-form-delivmeds-ai-pharmacychaintm-license?utm_source=chatgpt.com
2 replies
DancingQueen69 Oct 3, 9:29 AM
$MEDS My shares are not for borrowing.
1 replies
Natalie777 Oct 2, 11:08 PM
$NCT in at $1.49...let's go BULLS!!! $PFSA $MEDS $DCOY $ELPW
1 replies
Jobsworth Oct 2, 9:02 PM
$MEDS Runner AH retail shorts got greedy⬆️🚀✅🔥😂🔥
1 replies
Makeroni Oct 2, 8:20 PM
$MEDS $ADGM heading on up AH!
1 replies
DancingQueen69 Oct 2, 8:16 PM
$MEDS Datavault could be a major catalyst...exclusivity period ended Sept. 30 1. Closing still pending: MEDS lists the Datavault Transaction closing as a remaining H2 2026 milestone. 2. Much more than a partnership: The deal combines Datavault healthcare technology/licensing, QOLPOM IP and control of Tollo Health/Health Lives Here. 3. DVLT becomes a major shareholder: Proposed structure gives Datavault 19.9% of MEDS on a fully diluted basis. EOS and Scilex are also contemplated at 19.9% each. 4. Key condition already met: MEDS raised $6.5M, explicitly satisfying the deal’s capital-raising closing condition. 5. Timing is interesting: The LOI exclusivity period ended Sept. 30. No termination has been announced. 6. Dilution ≠ immediate float: The deal contemplates transfer restrictions and a 6-month lock-up for certain holders. A closing announcement could therefore be a major MEDS catalyst.
0 replies
DancingQueen69 Oct 2, 8:05 PM
$MEDS 1) Corexa growth: September preliminary revenue exceeded $1M, up 66%+ from July’s $600K+, implying a $12M+ annualized run rate if sustained. 2) Extreme borrow pressure: Last observed data showed 0 shares available to borrow and CTB around 539%. 3) Heavy short positioning: Reported short interest was ~430K shares / 33.85% of float, creating potential squeeze fuel if momentum returns. 4) Reg SHO Threshold: MEDS has been on the Threshold Securities List, indicating persistent settlement failures. Combined with scarce borrow, this matters. 5) Technical setup: Day 2 defended the $3.59–$3.60 support zone after Thursday’s +28% move. Monday is Day 3. A reclaim of $4+ could bring momentum back quickly.
0 replies
DancingQueen69 Oct 2, 7:53 PM
$MEDS I think we bought the last shares ❤️
0 replies